Welcome to our dedicated page for Medpace Holdings SEC filings (Ticker: MEDP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Medpace Holdings, Inc. filings document formal disclosures for a global clinical contract research organization, including 8-K reports that furnish quarterly and annual financial results. Those reports cover operating measures such as revenue, EBITDA, backlog conversion, net new business awards and book-to-bill ratios for its Phase I-IV clinical development services.
Medpace filings also include proxy materials addressing governance, executive compensation, equity awards and pay-versus-performance disclosure. Other material-event reports document credit-facility amendments involving operating subsidiaries and executive-officer succession matters.
Medpace Holdings, Inc. (MEDP) President & CEO August J. Troendle reported open-market sales of Medpace common stock. On September 15, 2026, he sold 15,971 shares at a weighted average price of $620.84, and on September 16, 2026, he sold 8,770 shares at a weighted average price of $621.29, for total reported sales of 24,741 shares.
The trades were effected pursuant to a limit order during an open window period. Troendle also reports 4,733,019 shares of Medpace common stock held indirectly through Medpace Investors, LLC, where he is the sole manager and controlling unitholder; he may be deemed to beneficially own those securities but disclaims beneficial ownership except to the extent of his pecuniary interest.
Medpace Holdings, Inc. (MEDP) executive Susan E. Burwig, Executive Vice President of Operations, exercised employee stock options for 3,000 shares of common stock on September 15, 2026 at an exercise price of $166.73 per share. The option, which vested in full on October 27, 2025 and expires on October 27, 2026, was converted into common stock, increasing her directly held common shares to 65,984. Following this transaction she continues to hold 8,028 stock options directly, and no Rule 10b5-1 trading plan is reported.
Medpace Holdings, Inc. (MEDP) reported that President & CEO August J. Troendle sold 650 shares of common stock on 2026-08-27 at a weighted average price of $620.27 per share in transactions effected pursuant to a limit order during an open window period. After this sale, he directly holds 539,894 shares. He is also the sole manager and controlling unit holder of Medpace Investors, LLC, which holds 4,733,019 shares; he may be deemed to indirectly beneficially own those shares but disclaims beneficial ownership except to the extent of his pecuniary interest.
For Medpace Holdings, Inc. (MEDP), director Robert O. Kraft reported an option exercise and same-day sale. On 2026-08-26, he exercised stock options for 3,858 shares of common stock at an exercise price of $84.36 per share, fully using an option that vested on May 13, 2021 and leaving 0 options from that grant outstanding. He then sold 3,858 common shares on the same date at a weighted average price of $617.81 per share, in multiple trades ranging from $617.73 to $618.43, and stands ready to provide detailed pricing information upon request.
Medpace Holdings, Inc. (MEDP) reported that President & CEO August J. Troendle sold common stock in two open-market transactions. On August 26, 2026, he sold 4,000 shares at a weighted average price of $620.03 per share, in multiple trades between $620.00 and $620.54. On August 25, 2026, he sold 673 shares at a weighted average price of $620.38 per share, in multiple trades between $620.00 and $621.89. The sales were effected pursuant to a limit order placed during an open window period. The filing also notes indirect ownership of 4,733,019 shares held by Medpace Investors, LLC, over which Troendle has sole voting and investment control, while he disclaims beneficial ownership except to the extent of his pecuniary interest.
Medpace Holdings, Inc. (MEDP) received a notice under Rule 144 that director Robert O. Kraft plans to sell restricted common stock. The planned sale covers 3,858 shares of common stock through Fidelity Brokerage Services LLC on or about August 26, 2026, in connection with a stock option exercise. The shares are listed on NASDAQ. The notice is signed on Kraft’s behalf by Fidelity as attorney-in-fact.
Medpace Holdings, Inc. (MEDP) reported that President & CEO and ten percent owner August J. Troendle sold a total of 15,978 shares of common stock. On August 21, 2026, he sold 13,995 shares at a weighted average price of $624.45 per share, with individual trades ranging from $620.00 to $628.685, effected under a limit order placed during an open window period. On August 24, 2026, he sold 1,983 shares at a weighted average price of $620.23 per share, with trades ranging from $620.00 to $621.25.
The filing also reports an indirect holding of 4,733,019 shares of Medpace common stock held by Medpace Investors, LLC, for which Troendle is the sole manager with sole voting and investment control. He may be deemed to indirectly beneficially own these securities but disclaims beneficial ownership except to the extent of his pecuniary interest.
Medpace Holdings, Inc. (MEDP) reported an insider equity transaction by Kevin M. Brady, its CFO & Treasurer. On August 20, 2026, he exercised employee stock options to acquire 3,400 shares of Common Stock at $138.87 per share and then sold 3,400 Common shares at $625.24 per share pursuant to a limit order placed during an open window period. Following the option exercise, he held 3,403 employee stock options of the same grant, which had vested in full on February 15, 2026 and carry an expiration date of August 15, 2027.
Medpace Holdings, Inc. (MEDP) reported that President & CEO August J. Troendle sold common stock in two open-market transactions. On August 20, 2026, he sold 27,174 shares at a weighted average price of $618.79 per share, and on August 19, 2026, he sold 15,609 shares at a weighted average price of $606.47 per share. Both were executed pursuant to a limit order during an open window period and involved multiple trades within disclosed price ranges. Following these transactions, Troendle is reported to indirectly hold 4,733,019 shares through Medpace Investors, LLC, where he has sole voting and investment control, while disclaiming beneficial ownership except to the extent of his pecuniary interest.
Medpace Holdings, Inc. (MEDP) director Brian T. Carley reported selling 5,000 shares of Medpace common stock on 2026-08-19 in an open-market or private transaction at a weighted average price of $608.63 per share, with individual trades ranging from $608.30 to $609.62. After this transaction, Carley directly holds 27,825 shares of Medpace common stock. The filing indicates the transaction was not made under a Rule 10b5-1 trading plan.